Wang Qingxue, Zhi Zheng, Han Hua, Zhao Qingtao, Wang Xing, Cao Shumin, Zhao Jing
Graduate School, Hebei North University, Zhangjiakou, Hebei 075000, P.R. China.
Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Oncol Lett. 2022 Dec 23;25(2):65. doi: 10.3892/ol.2022.13648. eCollection 2023 Feb.
Statins are lipid-lowering agents that have also been found to have anticancer effects. The relationship between statin use and clinical outcomes in ovarian cancer (OC) remains controversial, as previous assessments of the relationship between statin use and OC prognosis have yielded inconsistent results. Therefore, a comprehensive meta-analysis was performed in the present study to investigate this association. Studies were systematically retrieved by searching the PubMed, Embase and Cochrane Library databases, and consulting reference lists of the related studies. The search timeframe was from database creation to September 1, 2022. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the association. In the present meta-analysis, 16 studies with 37,660 patients with OC were included, of which 11,296 patients had been prescribed statins. The results showed that statin use markedly improved the overall survival time (OS; HR, 0.79; 95% CI, 0.73-0.85; P<0.00001) and OC-specific survival time (HR, 0.84; 95% CI, 0.80-0.89; P<0.00001), especially the OS time in patients with serous OC (HR, 0.81; 95% CI, 0.74-0.89; P<0.0001) and endometrioid OC (HR, 0.80; 95% CI, 0.66-0.98; P=0.03). In addition, survival rate was higher in patients who used statins after OC diagnosis (HR, 0.79; 95% CI, 0.73-0.85; P<0.00001). However, there was no statistically significant association between statin use and the prognosis of mucinous and clear cell OC. The results suggested that statin use markedly improved the OS in patients with OC, including in those with serous and endometrioid OC. Statins were also found to improve the prognosis of patients of both Asian and non-Asian ethnicities. In addition, both lipophilic and hydrophilic statins improved the survival in patients with OC, especially in patients using statins after OC diagnosis. However, the effect may vary depending on the statin type, duration of use and cancer type, and more well-designed studies are needed to further evaluate this.
他汀类药物是降脂药物，也被发现具有抗癌作用。他汀类药物的使用与卵巢癌（OC）临床结局之间的关系仍存在争议，因为先前对他汀类药物使用与OC预后关系的评估结果并不一致。因此，本研究进行了一项全面的荟萃分析来探究这种关联。通过检索PubMed、Embase和Cochrane图书馆数据库，并查阅相关研究的参考文献列表，系统地检索研究。检索时间范围是从数据库创建到2022年9月1日。计算合并风险比（HRs）及相应的95%置信区间（CIs）来评估这种关联。在本荟萃分析中，纳入了16项研究，共37660例OC患者，其中11296例患者曾使用过他汀类药物。结果显示，使用他汀类药物显著改善了总生存时间（OS；HR，0.79；95%CI，0.73 - 0.85；P<0.00001）和OC特异性生存时间（HR，0.84；95%CI，0.80 - 0.89；P<0.00001），尤其是浆液性OC患者（HR，0.81；95%CI，0.74 - 0.89；P<0.0001）和子宫内膜样OC患者（HR，0.80；95%CI，0.66 - 0.98；P = 0.03）的OS时间。此外，OC诊断后使用他汀类药物的患者生存率更高（HR，0.79；95%CI，0.73 - 0.85；P<0.00001）。然而，他汀类药物的使用与黏液性和透明细胞OC的预后之间没有统计学上的显著关联。结果表明，使用他汀类药物显著改善了OC患者的OS，包括浆液性和子宫内膜样OC患者。还发现他汀类药物改善了亚洲和非亚洲种族患者的预后。此外，亲脂性和亲水性他汀类药物均改善了OC患者的生存，尤其是OC诊断后使用他汀类药物的患者。然而，效果可能因他汀类药物类型、使用持续时间和癌症类型而异，需要更多设计良好的研究来进一步评估这一点。
